BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its…
Pharmaceuticals, Biotechnology and Life Sciences
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its…
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its…
PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…
PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…
SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid®…
EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid®…
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg…
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg…